Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 3, 2015, Pages 357-368

  Sullivan, Andrew ^a   Gibson, Andrew ^a   Park, Brian Kevin ^a   Naisbitt, Dean J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Chemically reactive metabolite; Drug hypersensitivity; Drug metabolism; T lymphocytes

Indexed keywords

ABACAVIR; ALLOPURINOL; ANESTHETIC AGENT; CARBAMAZEPINE; DRUG METABOLITE; PENICILLIN DERIVATIVE; SULFAMETHOXAZOLE; DRUG; PROTEIN;

ADAPTIVE IMMUNITY; ADVERSE DRUG REACTION; AEROBIC METABOLISM; ALLERGIC REACTION; ANALYTIC METHOD; CELLULAR IMMUNITY; CLINICAL FEATURE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PROTEIN BINDING; HEPATITIS; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; PATHOGENESIS; PENICILLIN ALLERGY; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

ANIMALS; DRUG HYPERSENSITIVITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LYMPHOCYTE ACTIVATION; PHARMACEUTICAL PREPARATIONS; PROTEINS; T-LYMPHOCYTES;

EID: 84923008431     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.992780     Document Type: Review

References (91)

1. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005;209(2):123-9
2. Hunziker T, Künzi UP, Braunschweig S, et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997;52(4):388-93
3. Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)-B∗57:01-restricted activation of drug-specific T-cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013;57(2):727-39
4. Spanou Z, Keller M, Britschgi M, et al. Involvement of drug-specific t cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 2006;17(10):2919-27
5. Green CF, Mottram DR, Rowe PH, et al. Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study. J Clin Pharm Ther 2000;25(5):355-61
6. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329(7456):15-19
7. Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital inpatients: A prospective analysis of 3695 patient-episodes. PLoS One 2009;4(2):e4439
8. Rawlins M, Thompson JW. Mechanisms of adverse drug reactions. University Press; Oxford: 1991. p. 18-45
9. Edwards I, Aronson J. Adverse drug reactions: definitions, diagnosis and management. Lancet 2000;356:1255-9
10. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998;11:969-88
11. Greene N, Naven R. Early toxicity screening strategies. Curr Opin Drug Discov Devel 2009;12(1):90-7
12. Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev 2013;65:779-808
13. Romano A, Torres MJ, Castells M, et al. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol 2011;127:S67-73
14. Pichler WJ. Drug-induced autoimmunity. Curr Opin Allergy Clin Immunol 2003;3:249-53
15. Coombs PR GP. Classification of allergic reactions responsible for clinical hypersensitivity and disease. Oxford University Press; Oxford, England;1968
16. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139(8):683-93
17. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy 2007;37(7):989-99
18. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935;61:643-56
19. Uetrecht J. Idiosyncratic drug reactions: past, present and future. Chem Res Toxicol 2008;21:84-92
20. Levine BB, Ovary Z. Studies on the mechanism of the formation of the penicillin antigen. III. The N-(D-alpha-benzylpenicilloyl) group as an antigenic determinant responsible for hypersensitivity to penicillin G. J Exp Med 1961;114:875-904
21. Lafaye P, Lapresie C. Fixation of penicilloyl groups to albumin and appearance of anti-penicilloyl antibodies to penicillin-treated patients. J Clin Invest 1988;82(1):7-12
22. Whitaker P, Meng X, Lavergne SN, et al. Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. J Immunol 2011;187(1):200-11
23. Jenkins RE, Meng X, Elliott VL, et al. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin Appl 2009;3(6):720-9
24. Ariza A, Collado D, Vida Y, et al. Study of protein haptenation by amoxicillin through the use of a biotinylated antibiotic. PLoS One 2014;9(3):e90891
25. Ariza A, Barrionuevo E, Mayorga C, et al. IgE to penicillins with different specificities can be identified by a multiepitope macromolecule: bihaptenic penicillin structures and IgE specificities. J Immunol Methods 2014;406:43-50
26. Brander C, Mauri-Hellweg D, Bettens F, et al. Heterogeneous T-cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. J Immunol 1995;155(5):2670-8
27. El-Ghaiesh S, Monshi MM, Whitaker P, et al. Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis. J Pharmacol Exp Ther 2012;341(3):597-610
28. Jenkins RE, Yaseen FS, Monshi MM, et al. Beta-lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis. Chem Res Toxicol 2013;26(6):963-75
29. Padovan E, Bauer T, Tongio MM, et al. Penicilloyl peptides are recognized as T-cell antigenic determinants in penicillin allergy. Eur J Immunol 1997;27(6):1303-7
30. Rozieres A, Vocanson M, Rodet K, et al. CD8+ T-cells mediate skin allergy to amoxicillin in a mouse model. Allergy 2010;65(8):996-1003
31. Pichler WJ, Yawalkar N, Britschgi M, et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002;3(4):229-38
32. Nhim C, Delluc S, Halgand F, et al. Identification and frequency of circulating CD4+ T lymphocytes specific to benzylpenicillin in healthy donors. Allergy 2013;68(7):899-905
33. Njoku D, Laster MJ, Gong DH, et al. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997;84(1):173-8
34. Holt M, Ju C. Drug-induced liver injury. In: Uetrecht J, editor. Adverse drug reactions. Springer; Berlin Heidelberg: 2010. p. 3-27
35. Sanderson J, Naisbitt D, Park BK. Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J 2006;8(1):E55-64
36. Bourdi M, Chen W, Peter RM, et al. Human Cytochrome P450 2E1 Is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996;9(7):1159-66
37. You Q, Cheng L, Ju C. Generation of T-cell responses targeting the reactive metabolite of halothane in mice. Toxicol Lett 2010;194(3):79-85
38. Schodin BA, Tsomides TJ, Kranz DM. Correlation between the number of T-cell receptors required for T-cell activation and TCR-ligand affinity. Immunity 1996;5(2):137-46
39. Pirmohamed M, Park BK. HIV and drug allergy. Curr Opin Allergy Clin Immunol 2001;1(4):311-16
40. Farrell J, Naisbitt DJ, Drummond NS, et al. Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J Pharmacol Exp Ther 2003;306(1):229-37
41. Whitaker P, Naisbitt D, Peckham D. Nonimmediate beta-lactam reactions in patients with cystic fibrosis. Curr Opin Allergy Clin Immunol 2012;12(4):369-75
42. Baier-bitterlich G, Fuchs D, Wachter H. Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Biochem Pharmacol 1997;53(6):755-63
43. Pichler WJ, Yawalkar N. Allergic reactions to drugs: involvement of T-cells. Thorax 2000;55(Suppl 2):S61-5
44. Sanderson JP, Naisbitt DJ, Farrell J, et al. Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol 2007;178(9):5533-42
45. Cribb AE, Spielberg SP. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab Dispos 1990;18(5):784-7
46. Cribb AE, Spielberg SP, Griffin GP. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995;23(3):406-14
47. Cribb AE, Miller M, Leeder JS, et al. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione: implications for idiosyncratic toxicity. Drug Metab Dispos 1991;19(5):900-6
48. Naisbitt DJ, Gordon SF, Pirmohamed M, et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 2001;133(2):295-305
49. Naisbitt DJ, Farrell J, Gordon SF, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 2002;62(3):628-37
50. Meekins CV, Sullivan TJ, Gruchalla RS. Immunochemical analysis of sulfonamide drug allergy: Identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 1994;94(6, Part 1):1017-24
51. Naisbitt DJ, Hough SJ, Gill HJ, et al. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999;126(6):1393-407
52. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004;59(8):809-20
53. Schnyder B, Mauri-Hellweg D, Zanni M, et al. MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T-cell clones. J Clin Invest 1997;100(1):136-41
54. Mauri-Hellweg D, Bettens F, Mauri D, et al. Activation of drug-specific CD4+ and CD8+ T-cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995;155(1):462-72
55. Watkins S, Pichler WJ. Sulfamethoxazole induces a switch mechanism in T-cell receptors containing TCRVbeta20-1, altering pHLA recognition. PLoS One 2013;8(10):e76211
56. Castrejon JL, Berry N, El-Ghaiesh S, et al. Stimulation of human T-cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol 2010;125(2):411-18; e4
57. Burkhart C, Von Greyerz S, Depta JP, et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Br J Pharmacol 2001;132(3):623-30
58. Schnyder B, Burkhart C, Schnyder-Frutig K, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T-cells from allergic individuals. J Immunol 2000;164(12):6647-54
59. Elsheikh A, Lavergne SN, Castrejon JL, et al. Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism. J Immunol 2010;185(11):6448-60
60. Elsheikh A, Castrejon L, Lavergne SN, et al. Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. J Allergy Clin Immunol 2011;127(6):1543-51; e3
61. Faulkner L, Martinsson K, Santoyo-Castelazo A, et al. The development of in vitro culture methods to characterize primary T-cell responses to drugs. Toxicol Sci 2012;127(1):150-8
62. Engler OB, Strasser I, Naisbitt DJ, et al. A chemically inert drug can stimulate T-cells in vitro by their T-cell receptor in non-sensitised individuals. Toxicology 2004;197(1):47-56
63. Alfirevic A, Vilar FJ, Alsbou M, et al. TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. Pharmacogenomics 2009;10(4):531-40
64. Alfirevic A, Stalford AC, Vilar FJ, et al. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 2003;55(2):158-65
65. Pirmohamed M, Alfirevic A, Vilar J, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000;10(8):705-13
66. Neuman MG, Shear NH, Malkiewicz IM, et al. Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides. Transl Res 2007;149(5):243-53
67. Spielberg S. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996;24(5):509-19
68. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens- Johnson syndrome. Nature 2004;428:486
69. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A∗3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-43
70. Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos 2002;30(11):1170-9
71. Pearce RE, Uetrecht JP, Leeder JS. Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos 2005;33(12):1819-26
72. Pearce RE, Lu W, Wang Y, et al. Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome p450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab Dispos 2008;36(8):1637-49
73. Wu Y, Sanderson JP, Farrell J, et al. Activation of T-cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006;118(1):233-41
74. Wei C-Y, Chung W-H, Huang H-W, et al. Direct interaction between HLA-B and carbamazepine activates T-cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012;129(6):1562-9; e5
75. Yun J, Mattsson J, Schnyder K, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T-cell response. Clin Exp Allergy 2013;43(11):1246-55
76. Hung S-I, Chung W-H, Liou L-B, et al. HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102(11):4134-9
77. Yun J, Marcaida MJ, Eriksson KK, et al. Oxypurinol directly and immediately activates the drug-specific T-cells via the preferential use of HLA-B∗58:01. J Immunol 2014;192(7):2984-93
78. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B∗ 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359(9308):727-32
79. Mallal S, Phillips E, Carosi G, et al. HLA-B∗5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358(6):568-79
80. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005;19(9):979-81
81. Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T-cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008;28(6):822-32
82. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012;486(7404):554-8
83. Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel self-peptides into HLA-B∗57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012;26(11):F21-9
84. Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 2012;109(25):9959-64
85. Bell CC, Faulkner L, Martinsson K, et al. T-cells from HLA-B∗57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms. Chem Res Toxicol 2013;26(5):759-66
86. Adam J, Eriksson KK, Schnyder B, et al. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol 2012;42(7):1706-16
87. Adam J, Wuillemin N, Watkins S, et al. Abacavir induced T-cell reactivity from drug naïve individuals shares features of allo-immune responses. PLoS One 2014;9(4):e95339
88. Walsh JS, Reese MJ, Thurmond LM. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem Biol Interact 2002;142(1-2):135-54
89. Meng X, Lawrenson AS, Berry NG, et al. Abacavir forms novel cross-linking abacavir protein adducts in patients. Chem Res Toxicol 2014;27(4):524-35
90. Martin SF, Esser PR, Schmucker S, et al. T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. Cell Mol Life Sci 2010;67(24):4171-84
91. Deshpande B, Chatterjee NR. Degradation of beta-lactam antibiotics. Curr Sci 2004;87(12):1684-94